Propranolol plus pembrolizumab for hard-to-treat breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have triple-negative breast cancer that cannot be cured by surgery or is metastatic
- Your cancer has grown despite prior chemotherapy plus pembrolizumab, but your doctor believes you can still stay on checkpoint treatment
- No chemotherapy, radiation, or major surgery in the last 4 weeks before starting the study treatment
- You must be willing to have a biopsy before treatment and again 6 weeks after starting the study
- You must meet basic blood and organ health levels (enough platelets, hemoglobin, neutrophils, liver and kidney function)
- You must be able to swallow and keep down pills, and be able to sign consent for study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy before surgery improves immune and clinical responses in people with early-stage triple-negative breast cancer. You may benefit by getting a potentially more effective treatment plan, while the study team closely monitors your response.
This Phase 1 study tests pembrolizumab (an immune medicine) to see how it affects the tumor and its surroundings in triple-negative breast cancer. It’s mainly looking at safety and early signs of benefit, especially in a limited, early-stage breast tumor.
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
Hear when a new Anatomic Stage III Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.